6.09 0.00 (0.00%)
After hours: 4:39PM EDT
|Bid||5.66 x 1000|
|Ask||7.69 x 800|
|Day's Range||5.70 - 6.20|
|52 Week Range||5.23 - 54.84|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.42|
NEW YORK, May 16, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Solid Biosciences Inc..
An analyst suggested investors look at Sarepta Therapeutics' array of gene therapies on Tuesday after rival Solid Biosciences reported its key gene therapy caused side effects in a patient.
(Bloomberg Opinion) -- It’s easy to get excited about gene therapies, a group of new medicines that have the potential to cure diseases in one treatment. The saga of Solid Biosciences Inc. is a reminder that tweaking genes isn’t a trivial task. These therapies are full of promise, but they’re not entirely there yet.
The gene therapy developer appears to be struggling to find a safe and effective dose of its experimental Duchenne muscular dystrophy treatment.
Solid Biosciences said in the earnings release that, among the two patients randomized in the second cohort of the Phase 1/2 study dubbed IGNITE, one was dosed with 2E14 vg/kg of its DMD gene therapy candidate and another was added to the control group. The patient in the treatment arm experienced a transient decline in platelet count, considered a serious adverse event, or SAE, related to the study. The patient also experienced a transient elevation of transaminases as well as a transient increase in bilirubin, higher than two times the upper limit of normal, which was reported as an SAE related to the study, the company said.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 13) BioSig Technologies Inc (NASDAQ: BSGM ) Milestone Pharmaceuticals ...
– Dosing of SGT-001 initiated in second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg – – Clinical activities underway at additional study sites –.
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
Bain Capital is in the process of raising money for a second life sciences fund, less than two years after it amassed $720 million for its inaugural fund targeting the fast-growing sector. Bain revealed the new fund in a securities filing last week. The filing does not say how much the Boston-based private equity firm is hoping to raise.
CAMBRIDGE, Mass., April 15, 2019 -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that preclinical data from its gene therapy program for Duchenne muscular dystrophy.
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
With one drug already being considered by the FDA, Sarepta Therapeutics Inc. is now planning to submit another drug for Duchenne muscular dystrophy to the FDA this year.
CAMBRIDGE, Mass., March 13, 2019 -- Solid Biosciences Inc. (NASDAQ: SLDB) today reported financial results for the fourth quarter and fiscal year ended December 31, 2018 and.
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
Roche Holdings AG Basel ADR (OTC: RHHBY )'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE ) has sparked a rally in the latter's shares. The Analysts ...
NEW YORK , Feb. 20, 2019 /PRNewswire/ -- Bristow Group Inc. (BRS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the Company disclosing that it "did ...
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Why Solid Biosciences Stock Nosedived 67.82% YesterdayStock price movements On February 7, Solid Biosciences (SLDB) closed at $7.19, 67.82% lower than its previous closing price, 5.27% higher than its 52-week low of $6.83, and 86.89% below its
Solid Biosciences crashed Thursday after its experimental gene therapy disappointed in a study of Duchenne muscular dystrophy patients. Sarepta Therapeutics, a rival, saw shares pop.